Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Natalizumab Extended Interval Dosing (EID) is Associated with a Reduced Risk of Progressive Multifocal Leukoencephalopathy (PML) Compared with Every-4-Week (Q4W) Dosing: Updated Analysis of the TOUCH® Prescribing Program Database

              Author:Zhovtis Ryerson, Lana   Foley, John   Kister, Ilya   Cutter, Gary   Metzger, Ryan   Goldberg, Judith   Li, Xiaochun   Riddle, Evan   Smirnakis, Karen   DSilva, Liesel   Sinks, Susie   Campbell, Nolan   Lasky, Tyler   Bodhinathan, Karthik   

              Session Name:P14: MS Clinical Practice  

              Topic:MS and Inflammatory Disease  

              Program Number:P14.011  

              Author Institution:Jersey Shore University Medical Center, Neptune, NJ  Rocky Mountain MS Clinic, Salt Lake City, UT  Department of Neurology, NYU Langone Health, New York University, New York, NY  University of Alabama At Birmingham School of Public Health, Birmingham, AL  New York University Grossman School of Medicine, Division of Biostatistics, New York, NY  Biogen, Cambridge, MA